NEU Stock Overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for NEU from our risk checks.
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$19.11 |
| 52 Week High | AU$25.90 |
| 52 Week Low | AU$10.02 |
| Beta | 1.99 |
| 1 Month Change | -11.49% |
| 3 Month Change | -16.37% |
| 1 Year Change | 38.28% |
| 3 Year Change | 1,453.66% |
| 5 Year Change | 1,621.62% |
| Change since IPO | 680.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NEU | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 1.1% | 3.0% | -1.5% |
| 1Y | 38.3% | 33.8% | 5.7% |
Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned 33.8% over the past year.
Return vs Market: NEU exceeded the Australian Market which returned 5.7% over the past year.
Price Volatility
| NEU volatility | |
|---|---|
| NEU Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: NEU's share price has been volatile over the past 3 months.
Volatility Over Time: NEU's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NEU fundamental statistics | |
|---|---|
| Market cap | AU$2.43b |
| Earnings (TTM) | AU$157.08m |
| Revenue (TTM) | AU$231.94m |
15.6x
P/E Ratio10.6x
P/S RatioIs NEU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEU income statement (TTM) | |
|---|---|
| Revenue | AU$231.94m |
| Cost of Revenue | AU$26.75m |
| Gross Profit | AU$205.19m |
| Other Expenses | AU$48.11m |
| Earnings | AU$157.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.23 |
| Gross Margin | 88.47% |
| Net Profit Margin | 67.72% |
| Debt/Equity Ratio | 0% |
How did NEU perform over the long term?
See historical performance and comparison